Evercrisp develops a non‑viral delivery platform that uses machine‑learning‑engineered miniproteins to transport protein and oligonucleotide therapeutics directly into specific cells via receptor‑mediated uptake. By avoiding viral vectors and nanoparticles, the system aims to improve safety, reduce required doses, and enable systemic treatment of diseases that were previously inaccessible to antisense, siRNA, or CRISPR‑based therapies. The platform also incorporates endosomal‑escape elements to enhance cytosolic delivery of genome‑editing complexes.
Funding
Funding not disclosed
Founders
Product
Problem
Genetic therapies such as antisense oligonucleotides, siRNAs, and CRISPR/Cas9 ribonucleoproteins often rely on viral vectors, nanoparticles, or ex vivo cell manipulation for delivery, which can cause safety concerns, require high systemic doses, and limit access to many tissues beyond the liver. These delivery constraints reduce therapeutic efficacy and restrict the range of diseases that can be treated with genetic medicines.
Solution
Evercrisk’s platform uses machine‑learning‑designed miniproteins that bind selected cell‑surface receptors to actively transport protein and oligonucleotide payloads into target cells. By leveraging receptor‑mediated endocytosis, the miniproteins enable lower‑dose, systemic administration without viral or nanoparticle carriers. Integrated endosomal escape elements promote cytosolic release, improving the potency of ASOs, siRNAs, and CRISPR/Cas9 ribonucleoproteins. The approach supports repeat dosing and can reach tissues that are currently inaccessible to conventional delivery methods, expanding the therapeutic scope of genetic medicines while enhancing safety profiles.
Target Audience
Primary customers are pharmaceutical and biotech companies developing genetic medicines that require safe, efficient delivery to specific tissues, as well as research organizations pursuing in‑vivo genome editing applications.
Features
- Machine‑learning engineered miniproteins that provide receptor‑specific binding for active cellular uptake
- Compatibility with diverse payloads, including antisense oligonucleotides, siRNAs, and CRISPR/Cas9 ribonucleoprotein complexes
- Built‑in endosomal escape motifs that increase cytosolic delivery efficiency and genome‑editing potency
- Systemic, repeatable dosing without reliance on viral vectors, lipid nanoparticles, or ex vivo cell processing
- Ability to target a broad range of non‑liver tissues through selection of appropriate cell‑surface receptors